Astra Merck Prilosec
Firm asserts patent protection for proton pump inhibitor through 2014 in suits filed against Andrx and Genpharm. The generic companies have filed ANDAs for omeprazole seeking to market versions of the world's top-selling drug when the basic substance patent expires in April 2001. Astra Merck, however, maintains that "the actions of Andrx and Genpharm infringe upon several other patents relating to Prilosec" which "include coverage for formulations as well as methods for using Prilosec"
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth